Details for New Drug Application (NDA): 205656

NDA 205656 describes ROCURONIUM BROMIDE, which is a drug marketed by Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, Mankind Pharma, Meitheal, Mylan Institutional, Piramal Critical, Prinston Inc, Rising, Sagent Pharms Inc, Sandoz, Shandong, Steriscience, Tamarang, Teva Pharms, West Ward Pharm Corp, and Sterinova Inc, and is included in twenty-one NDAs. It is available from twenty-four suppliers. There is one patent protecting this drug. Additional details are available on the ROCURONIUM BROMIDE profile page.

The generic ingredient in ROCURONIUM BROMIDE is rocuronium bromide. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.

Summary for 205656

Tradename:	ROCURONIUM BROMIDE
Applicant:	Gland
Ingredient:	rocuronium bromide
Patents:	0

Pharmacology for NDA: 205656

Physiological Effect

Neuromuscular Nondepolarizing Blockade

Suppliers and Packaging for NDA: 205656

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	205656	ANDA	Hospira, Inc.	0409-1403	0409-1403-10	10 VIAL, MULTI-DOSE in 1 CARTON (0409-1403-10) / 5 mL in 1 VIAL, MULTI-DOSE (0409-1403-05)
ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	205656	ANDA	Hospira, Inc.	0409-3189	0409-3189-10	10 VIAL, MULTI-DOSE in 1 CARTON (0409-3189-10) / 5 mL in 1 VIAL, MULTI-DOSE (0409-3189-05)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	50MG/5ML (10MG/ML)
Approval Date:	Apr 4, 2018	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	100MG/10ML (10MG/ML)
Approval Date:	Apr 4, 2018	TE:	AP	RLD:	No

Complete Access Available with Subscription